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OBJECTIVE—Use of gastric bypass surgery is common and increasing. Over 40% of patients
in diabetes remission after gastric bypass surgery may redevelop diabetes within 5 years. Met-
formin, the ﬁrst-line drug for diabetes, has low bioavailability and slow, incomplete gastrointes-
tinal absorption. We hypothesized that gastric bypass would further reduce the absorption and
bioavailability of metformin.
RESEARCH DESIGN AND METHODS—In a nonblinded, single-dose pharmacokinetic
study, 16 nondiabetic post–gastric bypass patients and 16 sex- and BMI-matched control subjects
(meanage40yearsandBMI39.2kg/m
2)wereadministeredtwo500-mgmetformintablets.Plasma
metforminlevelsweresampledat0.5,1,1.5,2,3,4,6,8,and24h.Metforminabsorption,estimated
by the area under the curve (AUC) of the plasma drug concentrations from time 0 to inﬁnity
(AUC0-∞), was the primary outcome, and metformin bioavailability, assessed by measuring 24-h
urine metformin levels, was a secondary outcome.
RESULTS—Compared with control subjects, metformin AUC0–∞ was increased in gastric
bypass subjects by 21% (13.7 vs. 11.4 mg/mL/h; mean difference 2.3 [95% CI 21.3 to 5.9])
and bioavailability was increased by 50% (41.8 vs. 27.8%; 14.0 [4.1–23.9]). Gastric bypass
patients had signiﬁcantly lower AUC glucose levels over 8 h compared with control subjects
(35.8 vs. 41.7 mg/mL/h; 5.9 [3.1–8.8]), but this was likely a result of differences in baseline
fasting glucose and not metformin absorption.
CONCLUSIONS—Metformin absorption and bioavailability seem to be higher after gastric
bypass,andthismayhaveimplicationsondosingandtoxicityrisk.Studiesareneededtoconﬁrm
these ﬁndings and delineate potential mechanisms.
Diabetes Care 34:1295–1300, 2011
B
ariatric surgery currently is indi-
cated in patients refractory to non-
surgical therapy with either severe
obesity (BMI $40 kg/m
2) or moderate
obesity(BMI35.0–39.9kg/m
2)a ndama -
jor obesity-related comorbidity (1). The
prevalence of moderate and severe obe-
sity has increased fourfold in recent de-
cades,and.5%ofthetotalpopulationin
the U.S. and Canada currently meet crite-
ria for surgical eligibility (2,3). The num-
ber of bariatric procedures performed
globally has increased 70-fold in the
past two decades, with nearly 350,000
procedures now performed annually (4).
Because the effectiveness of nonsurgical
treatments for obesity is widely consid-
ered to be limited, it is anticipated that
the use of surgery will continue to rapidly
increase (3).
Roux-en-Y gastric bypass (RYGB)
comprises 40% of bariatric procedures
(4). Gastric capacity is reduced by 95%,
and bypass of the duodenum and
proximal jejunum is performed. Because
RYGB is well documented to lead to nu-
trient malabsorption, it is possible that
clinically signiﬁcant reductions in drug
absorption also may occur after this pro-
cedure. However, this issue is poorly
studied, and no controlled trials have
been performed in RYGB patients (5).
Metformin hydrochloride currently
is considered to be the preferred initial
therapy for type 2 diabetes. Metformin
possesses several characteristics that in-
crease the potential for its malabsorption
after gastric bypass surgery. The drug
primarily is absorbed in the upper small
intestine (6) but has a relatively low oral
bioavailabilitythatrangesbetween29and
60% (7,8). Furthermore, metformin ab-
sorption is the rate-limiting step in drug
disposition because absorption is trans-
porter dependent and saturatable, which
causes bioavailability to diminish as dos-
age increases (7,9).
Over 40% of patients who initially
develop remission of their diabetes after
gastric bypass surgery may redevelop di-
abetes(10).Therefore,examiningmetfor-
min absorption after gastric bypass
surgery is of high clinical relevance. The
purpose of this controlled study was to
examine the single-dose pharmacokinet-
ics, including absorption and bioavail-
ability, of a standard-release preparation
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matched control subjects. To our knowl-
edge, this is the ﬁrst controlled examina-
tion of metformin pharmacokinetics in
post-RYGB subjects. Glycemic control
over an 8-h period also was compared be-
tween groups to assess if any observed
changes in bioavailability were concor-
dant with pharmacodynamic response.
RESEARCH DESIGN AND
METHODS—Sixteen post–gastric by-
passpatientsand16sex-andBMI-matched
(within 5 kg/m
2) control subjects, aged
18–60 years, were recruited through local
advertisements and from Edmonton
Weight Wise, a joint medical and surgical
regional obesity clinic. Informed consent
was obtained prior to study enrollment,
and ethics approval was granted by the
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Board. Surgical patients were $3 months
after surgery and were free of major post-
operative gastrointestinal complications
(e.g., anastamotic leak or outlet obstruc-
tion). Patients currently receiving metfor-
min or with contraindications to metformin
treatment were excluded. Contraindica-
tions included allergy, history of lactic/
metabolic acidosis, liver failure, baseline
liver enzymes higher than threefold above
theupperlimitofnormal,congestiveheart
failure, renal failure (glomerular ﬁltration
rate ,60 mL/min), alcoholism, fatty liver
disease,andacuteillness.Pregnantornurs-
ingmotherswereexcluded.Patientsreceiv-
ingfurosemideornifedipinewereexcluded
because both drugs may increase metfor-
min absorption by 15–20%.
All gastric bypass surgeries were per-
formed in standardized fashion. The gas-
tric pouch was formed using the pars
ﬂaccida technique. The anastamosis was
conducted using a 25 French Orvil EEA
device in an end-to-side fashion. Pouch
volumeswere25–30mLandthelengthof
the Roux (bypass) limb was 90–110 cm.
End points
The primary end point was metformin
absorption, estimated by the area under
the curve (AUC) of the plasma drug con-
centration from time 0 extrapolated to
inﬁnity (AUC0–∞).
Secondary outcomes included the
following:
1) Bioavailability of metformin, estimated
fromtheamountofmetforminexcreted
in the urine over 24 h;
2) AUCofmetforminabsorptionfrom0–
24 h (AUC0–24 h);
3) Time to peak drug concentration
(Tmax) and peak plasma drug con-
centration (Cmax); and
4) AUC of plasma glucose levels over the
ﬁrst 8 h of sampling (AUC0–8h).
Hypotheses and sample size
calculation
We hypothesized that metformin absorp-
tion would be signiﬁcantly reduced in
RYGB subjects compared with control sub-
jects. Assuming an AUC for a 1,000-mg
metformindoseof11.94mg/h/mL(SD2.71
mg/h/mL) (11) (a =0 . 0 5 ,b = 0.9), we esti-
mated that 13 patients would be required
ineach group to detect a 30% difference in
absorption between groups. Sixteen pa-
tients were enrolled per group to account
for variation in this estimate.
Pharmacokinetic and
pharmacodynamic testing
Pharmacokinetic studies were performed
in the clinical investigation unit of the
University of Alberta Hospital. Baseline
assessment included pregnancy testing
on all female participants within 2 weeks
of pharmacokinetic testing. Weight was
measured using a calibrated scale to the
nearest 0.1 kg, with the subject wearing
indoor clothing with empty pockets and
without shoes. BMI was calculated to the
nearest 10th unit by dividing the weight
in kilograms by the square of height in
meters (kg/m
2).
Subjects reported to the clinical in-
vestigation unit on the morning of their
testing date. After intravenous catheter
insertion, baseline fasting plasma metfor-
minandglucosesamplingwereperformed.
Subjects then ingested two 500-mg met-
formin hydrochloride (glucophage) tablets
at time 0. Twenty-four-hour urine collec-
tion for urinary metformin concentration
also commenced at time 0. Plasma met-
formin and glucose sampling was per-
formed0.5,1,1.5,2,3,4,6,and8hafter
metforminingestion.Standardizedmeals
were administered at 2 and 6 h after drug
administration, and a standardized snack
was given 4 h after drug administration.
Total caloric intake was 1,000 kcal (60%
carbohydrates). Subjects were required
to eat the entire meal. After the 8-h blood
draw, the patient was discharged and
returned the following morning for 24-h
blood sampling and to turn in the re-
mainder of the 24-h urine collection.
Samples were spun directly after col-
lection and were immediately stored at
270°C. A validated high-pressure liquid
chromatography assay was used to deter-
mine the plasma and urinary metformin
concentrations (12). The lower limit of
quantitation of the assay was 10 ng/mL.
The concentration of potassium phos-
phate used in the mobile phase was
25 mM.
Data entry and statistical analyses
Paper-based standardized case report
forms were populated, and data were
entered into a Microsoft Excel spread-
sheet using double-data entry. Analyses
were performed using Microsoft Excel
(version 2008; Microsoft), InStat (version
3.1a;GraphPadSoftware,SanDiego,CA),
and SAS (version 9.2; SAS Institute, Cary,
NC). Noncompartmental analysis was
used for calculation of pharmacokinetic
parameters. The plasma metformin con-
centration (Cmax) and time at which Cmax
occurred (Tmax) were determined directly
from the data. The terminal elimination
rate constant was estimated by applying
linear regression to the log-transformed
concentrations in the log-linear terminal
portion of the concentration-versus-time
curves. Terminal half-life was estimated
as 0.693 divided by the terminal elimina-
tionrateconstant.TheAUCconcentration-
versus-time curves of metformin (up to
24 h after dose) and glucose (up to 8 h
afterdose)weredeterminedusingthelin-
ear trapezoidal rule. TheAUC0–∞ of met-
formin concentrations was calculated by
adding to the AUC0–24 h the last mea-
sured concentration divided by the elim-
ination rate constant.
Because metformin is completely ex-
creted unchanged in the urine, urinary
recovery is indicative of the cumulative
amount of systemically available drug.
This allows estimation of bioavailability,
calculated by dividing urinary recovery
by total oral dose. Renal clearance was
estimated bydividing urinaryrecovery by
the AUC0–∞ of metformin concentra-
tions. Between-group differences in the
arithmetic means of continuous baseline
variables were analyzed using a paired
ttest(ifthenormalityassumptionpassed)
or a Mann-Whitney test (if the normality
assumptionfailed).AFisherexacttestwas
used for binary variables. Linear regres-
sion was performed to examine whether
AUC0–∞ metformin levels independently
predicted AUC0–8 glucose levels while
controlling for baseline glucose and
weight.The linearityassumptionwasver-
iﬁed using the runs test, and scatter and
residual plots were used to verify model
assumptions.
Two-tailed P values were considered
signiﬁcant at the 0.05 threshold.
RESULTS
Baseline characteristics
Mean age, BMI, and weight did not
signiﬁcantly differ between groups,
although a 10.6-kg-higher weight was
present in control subjects compared
with gastric bypass subjects (104.0 vs.
114.6 kg; P = 0.3) (Table 1). Fasting glu-
cose levels were signiﬁcantly greater in
control subjects (5.1 vs. 4.4 mmol/L; P =
0.0006), but HbA1c levels were virtually
identical between groups (Table 1). LDL
cholesterol was signiﬁcantly higher in
control subjects compared with gastric
bypass subjects (3.0 vs. 2.4 mmol/L; P =
0.02). Although one gastric bypass sub-
ject had a preoperative history of diabetes
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Gastric bypass and metformin absorptiontreated with metformin, this condition
was in remission postoperatively.
Absorption and bioavailability
Urineexcretionwasavailablein15gastric
bypass patients and 16 control subjects
because one urine sample was accidently
discarded prior to analysis.
Compared with control subjects,
gastric bypass subjects exhibited non-
signiﬁcant 21% increases in the AUC0–∞
compared with control subjects (13.7 vs.
11.4 mg/mL/h; mean difference 2.3 [95%
CI 21.3to5.9])(Fig.1andTable2).How-
ever, gastric bypass subjects demonstrated
50% higher bioavailability compared with
controlsubjects(41.8vs.27.8%;14.0[4.1–
23.9]). These differences remained statisti-
cally signiﬁcant after correction for baseline
body weight (Table2). There was little cor-
relation between AUC0–∞ metformin levels
and body weight (Pearson r = 20.3; P =
0.1).Ninety-eightpercentofrenalexcretion
took place within the ﬁrst 24 h.
Other pharmacokinetic parameters
Weight-normalized volume of distribu-
tion and weight-normalized renal clear-
ance were 40 and 43% higher (P , 0.05)
in gastric bypass subjects than control
subjects, respectively (Table 2). No
differences were found between groups
in Cmax, Tmax,o rh a l f - l i f e( T a b l e2 ) .
AUC0–8 glucose concentrations
TheAUC0–8glucoseconcentrationsinthe
gastric bypass patients were 14% lower
compared with control subjects (P ,
0.05) (Table 2 and Fig. 2). However,
AUC0–∞ metformin levels were not cor-
relatedwiththeAUC0–8glucoselevels(r=
20.02; P = 0.91). In multivariable linear
regression modeling, baseline fasting glu-
cose (parameter estimate 6.6; P , 0.0001)
was a signiﬁcant predictor of AUC0–8 glu-
cose, whereas weight was of borderline
signiﬁcance (0.03; P =0 . 0 8 )a n dA U C 0–∞
metforminlevelswerenotasigniﬁcantpre-
dictor (20.00005;P =0 . 5 )( o v e r a l lm o d e l -
adjusted R
2 =0 . 8 ) .
CONCLUSIONS—T h er a t ea n de x -
tent of absorption of metformin between
post-RYGB subjects and matched control
subjects was compared. Contrary to our
hypothesis, the metformin bioavailability
in RYGB subjects was signiﬁcantly in-
creased. Although the AUC0–8hglucose
level was signiﬁcantly lower in bypass
subjects compared with control subjects,
this ﬁnding was likely explained by base-
line differences in glucose levels and not
differences in metformin absorption.
RYGB is considered by some to be
procedure of choice in patients with type
2 diabetes because remission rates of type
2 diabetes are higher after RYGB com-
pared with gastric banding (the other
most commonly performed bariatric pro-
cedure). RYGB reduces average weight
to a greater extent than gastric banding
(43 vs. 29 kg) (13) and leads to favorable
neuroendocrine hormone-level altera-
tions that correlate with improved glyce-
mic control (14). Currently, ~15% of
patients undergoing bariatric surgery
have type 2 diabetes, and one-quarter of
these patients still require diabetes treat-
ment immediately after surgery (13).
Nearly all patients remain clinically obese
after surgery, and weight often is slowly
regained postoperatively (15). After 5
years, approximately 43% of diabetic pa-
tients in postoperative remission develop
recurrence (10). Therefore, assessing
metformin absorption after bariatric sur-
gery is of high clinical relevance because
many patients will require continuation
or reinitiation of metformin treatment
postoperatively.
M e t f o r m i na b s o r p t i o ni so fc l i n i c a l
relevancebecauserelationshipshavebeen
observed between its plasma concentra-
tion and its glucose-lowering and glucose-
regulating effects (9). With respect to its
biodisposition, metformin displays low
and variable bioavailability, is not metab-
olizedorexcretedinbile,is100%excreted
in the urine, and has a short terminal
half-life (4 h), meaning that nearly all of
the bioavailable dose is eliminated within
24 h (7–9). Therefore, unlike most drugs,
24-h urinary excretion can reliably esti-
mate bioavailability without requiring in-
travenous administration. Based on its
intrinsically low bioavailability and its ap-
parentprimarysiteformaximalabsorption
Table 1—Baseline characteristics
Variable Gastric bypass subjects Control subjects P
n 16 16
Age (years)* 44.4 (10.0) 43.5 (11.7) 0.82
Female sex† 13 (82) 13 (82) NA‡
BMI (kg/m
2)* 38.0 (7.9) 40.5 (6.9) 0.36
Weight (kg)* 104.0 (29.0) 114.6 (26.1) 0.30
Preoperative BMI (kg/m
2)* 51.5 (10.3) ——
Preoperative weight (kg)* 141.1 (35.9) ——
Time elapsed after bypass (months)* 17 (13.5) ——
Creatinine (mmol/L)* 62.9 (9.8) 65.2 (11.8) 0.56
Creatinine clearance (mL/min)* 91.3 (25.7) 95.7 (25.4) 0.63
A1C (%)* 5.5 (0.3) 5.6 (0.6) 0.28
Fasting glucose (mmol/L)* 4.4 (0.4) 5.1 (0.6) 0.0006
AST (units/L)* 22.6 (5.4) 25.3 (6.6) 0.22
Total cholesterol (mmol/L)* 3.96 (0.69) 4.78 (1.08) 0.02
Triglycerides (mmol/L)* 1.0 (0.33) 1.5 (0.88) 0.29§
HDL cholesterol (mmol/L)* 1.1 (0.25) 1.1 (0.38) 0.74
LDL cholesterol (mmol/L)* 2.4 (0.53) 3.0 (1.02) 0.03
Hypertension† 8 (50) 7 (43.8) 1.0
Type 2 diabetes† 1( 6 . 3 ) | 0( 0 ) 1 . 0
Dyslipidemia† 1 (6.3) 4 (0.25) 0.33
Hypothyroidism† 3 (0.38) 2 (0.13) 1.0
Sleep apnea† 7 (43.8) 4 (0.25) 0.46
Gastrointestinal reﬂux† 1 (6.3) 4 (0.25) 0.33
*Data are mean (SD). †Data are n (%). ‡Subjects were sex-matched. §Mann-Whitney U statistic. |Diabetes in
remission after RYGB.
Figure 1—Plasma concentration time curve.
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Padwal and Associatesin the proximal small intestine, which
possesses the largest overall surface area
per unit length of the entire gut (16), we
theorized that absorption would be
diminished after RYGB, a procedure that
bypassestheproximalsmallintestine.The
results provided several unexpected out-
comes, including not only increased bio-
availability but also increases in volume of
distribution and renal clearance.
For the increase in the extent of
absorption, several potential mechanisms
may explain the results, including the
following:
1) RYGB performed with pouch volumes
of 60–80 mL seems to delay gastric
emptying for solid foods (17). In
addition, RYGB increases intestinal
transit time (18,19). Although data
examining more contemporary pouch
sizes (30 mL) and pills rather than
food are lacking, we speculate that
these gastrointestinal alterations may
increase the overall absorption of met-
formin by increasing the duration
of exposure of the drug to small-
intestinal mucosa. The absorption of
metformin is permeability rate limited,
and the drug is almost exclusively ab-
sorbed in the small intestine (6,7,9).
The drug that reaches the colon is not
absorbed and is fecally excreted, with
~30% of the drug being eliminated in
this manner (6). Because metformin
has a limited window for absorption
andabsorptionisincomplete,prolonging
the intestinal transit time increases ab-
sorption (20). Similarly, delaying gastric
emptying may decrease the rate at
which the drug enters the small bowel,
thuspreventingsaturationofabsorptive
mechanisms and increasing overall
absorption (18). Slow-release formula-
tions of metformin act in an analogous
manner;thedrugisphysicallyretainedin
the stomach and released gradually into
the upper small bowel, resulting in sus-
tained and prolonged steady-state met-
formin levels (21).
2) After RYGB, the newly created 20- to
30-mL gastric pouch is largely devoid
of acid-producing cells, and acid se-
cretion is virtually absent (22). Al-
though this more alkaline environment
may potentially enhance the solubility
of an acidic drug, metformin is a base,
with a pKa of 12.4–13.8 and is almost
completely ionized at all ranges of in-
testinal pH (23). Therefore, increases
in intestinal pH are unlikely to play a
major role in increasing metformin
absorption after bypass.
3) Metformin is a substrate for organic
cation transporters (OCTs), examples
ofwhichincludehumanOCTs1and2
(hOCT1 and -2), which are primarily
found in the liver and kidney, and
plasma membrane monoamine trans-
porter in the intestine (23). Absorption
in the intestinal tract appears to occur
both transcellularly, which appears de-
pendent upon OCTs (23), and para-
cellularly, which occurs via facilitated
diffusion and may account for up to
90% of absorption (24). We speculate
that alterations in these transport mech-
anisms,suchastransporterupregulation,
may be occurring after surgery, which
may explain our ﬁndings.
4) Small-intestinal adaptation resulting
from villous hyperplasia and possibly
related to increased luminal nutrient
exposure is a phenomenon that has
been described after bowel resection
(24). In theory, a similar mechanism
mayoccuraftergastricbypass,although
this has not been previously described
in this patient population.
We documented a 50% increase in
the bioavailability of metformin, which is
large enough to be potentially clinically
relevant, particularly if sustained with
chronic dosing and especially in the
presence of renal dysfunction. We did
not ﬁnd a relationship between increased
absorption and reduced AUC glucose
levels, but this was not unexpected. Pre-
vious studies have demonstrated that
Table 2—Pharmacokinetic and pharmacodynamic outcomes
Variable
Gastric bypass
subjects
Control
subjects
Mean difference
(95% CI) P
n 16 16
Pharmacokinetic outcomes
AUC0–∞ (mg/h/mL) 13.7 (6.0) 11.4 (3.6) 2.3 (21.3 to 5.9) 0.20
Bioavailability (%) 41.8 (16.2)* 27.8 (10.4) 14.0 (4.1–23.9) 0.007
AUC0–24 h (mg/h/mL) 13.4 (5.7) 11.1 (3.6) 2.2 (21.3 to 5.6) 0.20
Cmax (mg/mL) 2.0 (0.86) 1.8 (0.61) 0.2 (20.3 to 0.8) 0.32
Tmax (h) 3.0 (1.5–3.0)† 3.0 (1.5–3.0)† 0( 0 ) † 0.89†
Half-life (h) 3.9 (0.74) 4.0 (0.87) 20.1 (20.7 to 0.5) 0.66
Urinary recovery (0–24 h) (mg) 326 (126) 217 (81) 140 (41–239) 0.007
Weight-normalized urinary recovery (0–24 h; mg/kg) 3.1 (1.2)* 2.0 (0.78) 1.5 (0.5–2.5) 0.003
Renal clearance (mL/min) 461 (199)* 337 (131) 125 (1.5–248) 0.047
Weight-normalized renal clearance (mL/min/kg) 4.3 (1.6)* 3.0 (1.0) 1.3 (0.3–2.3) 0.009
Weight-normalized volume of distribution (L/kg) 1.4 (0.4) 1.0 (0.4) 0.4 (0.1–0.7) 0.02
Pharmacodynamic outcome
AUC glucose0–8h(mmol/mL/h) 35.8 (3.7) 41.7 (4.1) 5.9 (3.1–8.8) 0.0002
Data are means (SD), unless otherwise indicated. *Sample size was 15. One sample was lost. †Numbers are median (range). Mann-Whitney U statistic used.
Figure 2—Glucose concentration time curve.
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Gastric bypass and metformin absorptionmetformin has little effect on glucose
levels in nondiabetic patients unless toxic
levels of the drug are administered (7).
Furthermore, even in diabetic subjects,
single doses of metformin have no effect
onpreprandialglucoseanddoses.1,700
mgarerequiredtoaffectpostprandialglu-
cose levels (9). Therefore, a notable effect
on glucose levels would not be expected
after administration of a single dose to
nondiabetic subjects even if bioavailabil-
ity increased by .50%.
In addition to the increase in oral
bioavailability, higher metformin volume
of distribution and renal clearance values
in the surgical patients were found. The
currentstudywasnotdesignedtoprovide
insightintomechanismsunderlyingthese
interesting observations. It was apparent
that the creatinine plasma concentrations
and clearances were highly similar in the
two groups (Table 1). Because metformin
has low plasma protein binding and is ef-
ﬁciently renally secreted, the difference in
renal clearance in the surgical patients
may be a consequence of more efﬁcient
secretion, perhaps mediated by OCT2.
A limitation of our study was that a
single dose was administered to fasting
subjects. Fasting subjects were studied to
minimize the effect of food on metformin
absorption (food decreases absorption by
~25%)(25).Althoughsingle-dosestudies
are easier to perform and are typically
used to gain initial insight into an area,
they have the drawback of not being
able to assess steady-state levels. In clini-
cal practice, multiple doses of metformin
typicallyareadministeredwithfood.Thus,
additional study examining steady-state
levels in nonfasting subjects would
be required to more closely mimic clinical
practice. An additional limitation to our
study was that nonsigniﬁcant differences
in body weight and signiﬁcant differences
in metabolic parameters, including fasting
glucose levels, were present at baseline.
We also cannot rule out the possibility
that secondary metabolic changes in
unmeasured parameters occurring after
gastric bypass (e.g., thyroid hormone al-
terations) inﬂuenced our results. In our
analysis, adjustment for body weight was
performed for relevant pharmacokinetic
parameters and results were unchanged.
Because metformin absorption does not
vary according to diabetes status (7), the
baselinebetween-groupdifferencesinglu-
coselevelsareunlikelytoexplainourﬁnd-
ings regarding metformin bioavailability.
A post hoc analysis examining between-
groupdifferencesinbioavailabilitycorrected
forbaselineglucoselevelsdidnotchangethe
results (9.6 vs. 5.4% z L/mmol;mean differ-
ence 24.2 [95% CI 22.0 to 26.5]).
In conclusion, metformin absorption
and bioavailability were unexpectedly in-
creased in gastric bypass subjects com-
pared with control subjects. Therefore,
factors other than diminished small-
bowel length inﬂuence overall metformin
absorption. This has potential implica-
tions for metformin dosing after bypass
and for medications with similar pharma-
cological properties. Studies are needed
to conﬁrm these ﬁndings and delineate
potential mechanisms.
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